jpm17

ABBVIE ANNOUNCES FOUR NEW GLOBAL RESEARCH COLLABORATIONS

January 9, 2017

AbbVie, a global biopharmaceutical company, has announced four new collaborations and investments with leading healthcare innovators for advancing early-stage research in key therapeutic areas such as immunology and oncology. The company is committed to investing in and developing transformational science and technologies to advance the next-generation of therapies across its robust pipeline in key therapeutic areas.

TAKEDA ACQUIRES ARIAD IN $5.2B DEAL

January 9, 2017

Takeda, a prominent Japanese drugmaker, provided the first major deal of the J.P. Morgan Healthcare Conference. The company announced a takeover of Ariad Pharmaceuticals which valued the cancer specialist at $5.2 billion.

IPSEN ACQUIRING ONCOLOGY ASSETS FROM MERRIMACK PHARMACEUTICALS

January 9, 2017

Ipsen will gain exclusive commercialization rights for the current and potential future of ONIVYDE indications in the U.S. The transaction also includes the commercial and manufacturing infrastructure of Merrimack, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is an FDA-approved and clinically differentiated product for treating metastatic pancreatic cancer in adult patients.

INTARCIA AND CALIBR ANNOUNCE COLLABORATION AND IN-LICENSING DEAL

January 9, 2017

Intarcia Therapeutics, Inc. and the California Institute for Biomedical Research (Calibr) have announced a strategic research collaboration focused on the development of a novel peptide therapeutic leveraging Calibr’s Stapled-Peptide Platform Technology. Intarcia plans to develop and administer this novel therapy in combination with Exenatide (a GLP-1 receptor agonist and active agent in Intarcia’s ITCA 650 product), by leveraging its proprietary Medici Drug Delivery SystemTM.

MODERNA PROVIDES PIPELINE AND FULL-YEAR CORPORATE UPDATE

January 9, 2017

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) Therapeutics™ to create a new generation of transformative medicines for patients, provided a business update at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. Moderna’s Chief Executive Officer, Stéphane Bancel, highlighted the company’s current development pipeline, which includes 12 mRNA development candidates (DCs), including vaccines and therapeutics across three therapeutic areas: infectious diseases, immuno-oncology and cardiovascular disease. Clinical studies for five of the DCs are now underway in the U.S., Europe and Australia. Among these is Moderna’s Zika mRNA vaccine, mRNA-1325, which the company progressed from idea to first-in-human study in 12 months. Moderna has filed two additional investigational new drug (IND) applications with the U.S. Food & Drug Administration (FDA); one of these INDs is now open and the other was filed in late December 2016.

ALLERGAN PARTNERSHIPS WITH ASSEMBLY BIOSCIENCES AND LYSOSOMAL THERAPEUTICS

January 10, 2017

Allergan has announced that it has reached separate agreements to partner with both Lysosomal Therapeutics and Assembly Biosciences for research and development. These announcements were released at the J.P. Morgan Healthcare Conference 2017.

VALEANT SELLS OFF DENDREON, SKINCARE BRANDS FOR $2.1B

January 10, 2017

Valeant Pharmaceuticals, weighed down by a mountain of debt and doubts that won’t disappear, announced the first major asset sales since CEO Joseph Papa took over last May, selling its Dendreon unit to the Chinese Sanpower Group for $820 million and three skincare brands to L’Oréal for $1.3 billion.

BRESCH CALLS OUT PRICING TRANSPARENCY

January 11, 2017

Mylan CEO Heather Bresch told a packed room at the Westin St. Francis in San Francisco that it’s time for the way the industry does business to change. The executive made headlines throughout 2016 for the sharp price increases of the company’s allergic reaction medication EpiPen. Bresch talked about drug pricing and lessons learned during the EpiPen controversy at the 35th annual J.P. Morgan Healthcare Conference.

INSULIN DRUG OFFERS HOPE FOR MANNKIND

January 12, 2017

Inhalable insulin developer MannKind was optimistic about the relaunch of its insulin Afrezza, despite the drug largely being a commercial flop and big pharma partner Sanofi pulling out of the deal. CEO Matt Pfeffer said MannKind has ended a pact with its contract sales organization and is hoping to hire 65 sales reps of its own as it continues to push Afrezza forward.

Advertisements

One thought on “The Very Best of JPM Healthcare Conference 2017

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s